(Q90547590)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

title

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

Rachna T Shroff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Andrew Hendifar

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Robert R McWilliams

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Ravit Geva

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Ron Epelbaum

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Lindsey Rolfe

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Sandra Goble

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Kevin K Lin

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Andrew V Biankin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Heidi Giordano

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Robert H Vonderheide

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Susan M Domchek

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

publication date

16 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

published in

JCO Precision Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

volume

2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

14 April 2020

cites work

1 reference

12 December 2020

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

12 December 2020

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

1 reference

12 December 2020

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

12 December 2020

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

1 reference

12 December 2020

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

1 reference

12 December 2020

5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma

1 reference

12 December 2020

The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings

1 reference

12 December 2020

Links between genome integrity and BRCA1 tumor suppression.

1 reference

12 December 2020

Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials

1 reference

12 December 2020

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

1 reference

12 December 2020

5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy

1 reference

12 December 2020

Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States

1 reference

12 December 2020

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

1 reference

12 December 2020

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

12 December 2020

Whole genomes redefine the mutational landscape of pancreatic cancer

1 reference

12 December 2020

Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials

1 reference

12 December 2020

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

1 reference

12 December 2020

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

1 reference

12 December 2020

Genomic analyses identify molecular subtypes of pancreatic cancer

1 reference

12 December 2020

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

1 reference

12 December 2020

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

1 reference

12 December 2020

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

1 reference

12 December 2020

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

1 reference

12 December 2020

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers

1 reference

12 December 2020

Identifiers

DOI

10.1200/PO.17.00316

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30051098%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

PubMed publication ID

30051098

1 reference